Ajanta Pharma Board Meeting for Q2 FY27 Results

This is a regulatory disclosure made by Ajanta Pharma Limited pursuant to Regulation 29 of the SEBI Listing Regulations.

The Board of Directors of the Company will hold a meeting on Friday, 30th October 2026.

The primary purpose of the meeting is to consider and approve the following financial results:

• The unaudited standalone financial results for the second quarter ended 30th September 2026.
• The unaudited consolidated financial results for the second quarter ended 30th September 2026.
• The unaudited standalone financial results for the half year ended 30th September 2026.
• The unaudited consolidated financial results for the half year ended 30th September 2026.

The notice was issued by Gaurang Chinubhai Shah, Sr. VP – Legal & Company Secretary, from the company's registered office at Ajanta Tower, 54-A, M Vasanji Road, Chakala, Andheri (E), Mumbai 400 093.

The financial results themselves are not disclosed in this notice and are pending board approval.